Nanostring Technologies Inc (NSTG) 12.66 $NSTG
NanoString Technologies to Release Fourth Quarter 2014 Financial Results and Host Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Tue Feb 10, 3:07PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter 2014 financial results after the close of trading on Tuesday, February 24, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.66 (-0.11)
Labcyte Names Chris Grimley as Vice President of Marketing
Business Wire - Mon Feb 09, 7:08AM CST
Labcyte Inc., the company revolutionizing life science research with the Echo(R) liquid handler, today announced the appointment of Chris Grimley as Vice President of Marketing. Mr. Grimley will be responsible for leading the global marketing and product management teams, driving demand for products and services, and growing sales of the Echo liquid handler in emerging application areas such as in synthetic biology, next generation sequencing and personalized medicine.
NSTG: 12.66 (-0.11), A: 40.15 (+0.13)
NanoString Technologies to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Jan 28, 7:09AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York.
NSTG: 12.66 (-0.11)
NanoString Technologies Provides Update on 2014 Operational and Preliminary Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
- Expected Full Year 2014 Revenue Growth of 50% to 53% Year over Year -
NSTG: 12.66 (-0.11)
NanoString Technologies to Present at J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Mon Dec 22, 7:00AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the J.P. Morgan 33 Annual Healthcare Conference in San Francisco.
NSTG: 12.66 (-0.11), JPM: 59.67 (+0.10)
NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 15, 3:05PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the results of the first Prosigna(R) Assay decision impact study presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) showed that the use of the test significantly changed oncologists' treatment recommendations. Conducted in collaboration with Grupo Espanol de Investigacion del Cancer de Mama (GEICAM), a Spanish breast cancer research group, this prospective study of the Prosigna Assay and its impact on the treatment of women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer showed that the use of the test informed the oncologists' recommendation whether or not to treat with adjuvant chemotherapy in addition to adjuvant endocrine therapy.
NSTG: 12.66 (-0.11)
NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis
Business Wire - Mon Dec 08, 3:40PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has cleared a labeling update for the Prosigna(R) Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-
, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive (ER+) early-stage breast cancer.
NSTG: 12.66 (-0.11)
NanoString Technologies Announces Prosigna Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 01, 3:05PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that multiple posters for the Prosigna(R) Breast Cancer Gene Signature Assay based on PAM50 will be presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). These include a prospective study of the Prosigna Assay on adjuvant clinical decision-making in women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer. This decision impact study, performed in conjunction with Grupo Espanol de Investigacion del Cancer de Mama (GEICAM), a Spanish breast cancer research group, is the first of its kind to provide insights into the changes in clinical practice derived from the use of the Prosigna Assay.
NSTG: 12.66 (-0.11)
NanoString Technologies to Present at Canaccord Genuity Medical Technology and Diagnostics Forum
GlobeNewswire - Fri Nov 07, 7:38AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City.
NSTG: 12.66 (-0.11)
NanoString Technologies' (NSTG) CEO Brad Gray on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:29PM CST
NSTG: 12.66 (-0.11)
NanoString misses by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:10PM CST
NSTG: 12.66 (-0.11)
NanoString Technologies Releases Financial Results for Third Quarter of 2014
GlobeNewswire - Tue Nov 04, 3:02PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter ended September 30, 2014.
NSTG: 12.66 (-0.11)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer
Business Wire - Tue Oct 21, 3:00PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the Journal of Clinical Oncology published an analysis of data in over 2,100 patients showing that the risk-of-recurrence (ROR) score generated by the PAM50-based Prosigna(TM) Breast Cancer Assay predicts the risk of late distant recurrence, after five years of endocrine therapy, in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. These results, in combination with previously published clinical studies, demonstrate the potential for Prosigna to inform both the use of adjuvant chemotherapy and the use of extended adjuvant endocrine therapy based on a single risk score.
NSTG: 12.66 (-0.11)
NanoString Technologies to Release Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
GlobeNewswire - Thu Oct 09, 3:10PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2014 financial results after the close of trading on Tuesday, November 4, 2014. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.66 (-0.11)
NanoString Collaborates with Brigham and Women's Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology
Business Wire - Mon Oct 06, 3:00PM CDT
NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString's Elements(TM) reagents, assays will be developed to detect gene expression, copy number variations, and fusions from a diverse range of tumor samples.
NSTG: 12.66 (-0.11)
NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research
Business Wire - Tue Sep 09, 3:00PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the introduction of a new highly multiplexed gene expression panel for the nCounter(R) Analysis System, the PanCancer Immune Profiling Panel. This novel panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies and predictive biomarker signatures for immunotherapy treatment response.
NSTG: 12.66 (-0.11)
Booming Biotech Market Benefits REIT BioMed Realty
at Investor's Business Daily - Tue Sep 02, 4:42PM CDT
Biotech stocks are on the move again. So is a real estate investment trust that leases office and lab space to life science companies. San Diego is home to professional sports teams such as the Chargers and Padres. It's also a biotech hotbed -- which...
BMR: 22.85 (-0.13), NSTG: 12.66 (-0.11), NVO: 43.76 (+0.61), BMY: 60.04 (+0.56)
NanoString reports demise of CMO Dr J. Wayne Cowens
M2 - Thu Aug 28, 5:55AM CDT
Life science company NanoString Technologies (NasdaqGM:NSTG) disclosed on Wednesday that its chief medical officer Dr Cowens has died suddenly at the age of 67.
NSTG: 12.66 (-0.11)
NanoString Technologies to Release Fourth Quarter 2014 Financial Results and Host Conference Call on Tuesday, February 24, 2015
GlobeNewswire - Tue Feb 10, 3:07PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter 2014 financial results after the close of trading on Tuesday, February 24, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.66 (-0.11)
Labcyte Names Chris Grimley as Vice President of Marketing
Business Wire - Mon Feb 09, 7:08AM CST
Labcyte Inc., the company revolutionizing life science research with the Echo(R) liquid handler, today announced the appointment of Chris Grimley as Vice President of Marketing. Mr. Grimley will be responsible for leading the global marketing and product management teams, driving demand for products and services, and growing sales of the Echo liquid handler in emerging application areas such as in synthetic biology, next generation sequencing and personalized medicine.
NSTG: 12.66 (-0.11), A: 40.15 (+0.13)
NanoString Technologies to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Wed Jan 28, 7:09AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York.
NSTG: 12.66 (-0.11)
NanoString Technologies Provides Update on 2014 Operational and Preliminary Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
- Expected Full Year 2014 Revenue Growth of 50% to 53% Year over Year -
NSTG: 12.66 (-0.11)
NanoString Technologies to Present at J.P. Morgan 33rd Annual Healthcare Conference
GlobeNewswire - Mon Dec 22, 7:00AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the J.P. Morgan 33 Annual Healthcare Conference in San Francisco.
NSTG: 12.66 (-0.11), JPM: 59.67 (+0.10)
NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 15, 3:05PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the results of the first Prosigna(R) Assay decision impact study presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) showed that the use of the test significantly changed oncologists' treatment recommendations. Conducted in collaboration with Grupo Espanol de Investigacion del Cancer de Mama (GEICAM), a Spanish breast cancer research group, this prospective study of the Prosigna Assay and its impact on the treatment of women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer showed that the use of the test informed the oncologists' recommendation whether or not to treat with adjuvant chemotherapy in addition to adjuvant endocrine therapy.
NSTG: 12.66 (-0.11)
NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis
Business Wire - Mon Dec 08, 3:40PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has cleared a labeling update for the Prosigna(R) Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-
, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive (ER+) early-stage breast cancer. NSTG: 12.66 (-0.11)
NanoString Technologies Announces Prosigna Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 01, 3:05PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that multiple posters for the Prosigna(R) Breast Cancer Gene Signature Assay based on PAM50 will be presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). These include a prospective study of the Prosigna Assay on adjuvant clinical decision-making in women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer. This decision impact study, performed in conjunction with Grupo Espanol de Investigacion del Cancer de Mama (GEICAM), a Spanish breast cancer research group, is the first of its kind to provide insights into the changes in clinical practice derived from the use of the Prosigna Assay.
NSTG: 12.66 (-0.11)
NanoString Technologies to Present at Canaccord Genuity Medical Technology and Diagnostics Forum
GlobeNewswire - Fri Nov 07, 7:38AM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City.
NSTG: 12.66 (-0.11)
NanoString Technologies' (NSTG) CEO Brad Gray on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:29PM CST
NSTG: 12.66 (-0.11)
NanoString misses by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:10PM CST
NSTG: 12.66 (-0.11)
NanoString Technologies Releases Financial Results for Third Quarter of 2014
GlobeNewswire - Tue Nov 04, 3:02PM CST
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter ended September 30, 2014.
NSTG: 12.66 (-0.11)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer
Business Wire - Tue Oct 21, 3:00PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the Journal of Clinical Oncology published an analysis of data in over 2,100 patients showing that the risk-of-recurrence (ROR) score generated by the PAM50-based Prosigna(TM) Breast Cancer Assay predicts the risk of late distant recurrence, after five years of endocrine therapy, in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. These results, in combination with previously published clinical studies, demonstrate the potential for Prosigna to inform both the use of adjuvant chemotherapy and the use of extended adjuvant endocrine therapy based on a single risk score.
NSTG: 12.66 (-0.11)
NanoString Technologies to Release Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014
GlobeNewswire - Thu Oct 09, 3:10PM CDT
NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2014 financial results after the close of trading on Tuesday, November 4, 2014. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
NSTG: 12.66 (-0.11)
NanoString Collaborates with Brigham and Women's Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology
Business Wire - Mon Oct 06, 3:00PM CDT
NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString's Elements(TM) reagents, assays will be developed to detect gene expression, copy number variations, and fusions from a diverse range of tumor samples.
NSTG: 12.66 (-0.11)
NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research
Business Wire - Tue Sep 09, 3:00PM CDT
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the introduction of a new highly multiplexed gene expression panel for the nCounter(R) Analysis System, the PanCancer Immune Profiling Panel. This novel panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies and predictive biomarker signatures for immunotherapy treatment response.
NSTG: 12.66 (-0.11)
Booming Biotech Market Benefits REIT BioMed Realty
at Investor's Business Daily - Tue Sep 02, 4:42PM CDT
Biotech stocks are on the move again. So is a real estate investment trust that leases office and lab space to life science companies. San Diego is home to professional sports teams such as the Chargers and Padres. It's also a biotech hotbed -- which...
BMR: 22.85 (-0.13), NSTG: 12.66 (-0.11), NVO: 43.76 (+0.61), BMY: 60.04 (+0.56)
NanoString reports demise of CMO Dr J. Wayne Cowens
M2 - Thu Aug 28, 5:55AM CDT
Life science company NanoString Technologies (NasdaqGM:NSTG) disclosed on Wednesday that its chief medical officer Dr Cowens has died suddenly at the age of 67.
NSTG: 12.66 (-0.11)
